Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson’s Disease: A Systematic Review and Network Meta-Analysis
To evaluate the comparative efficacy and safety of ropinirole and pramipexole as adjunctive therapies to levodopa (l-dopa) for the management of advanced Parkinson’s disease (PD), via a systematic review and network meta-analysis.
Twenty-one double-blind randomised controlled trials of patients with advanced PD with motor fluctuations receiving l-dopa comparing ropinirole or pramipexole with comparators were identified from 2550 publications. Bayesian indirect comparison methods were applied to independently review efficacy outcomes including off-time reduction, Unified Parkinson's Disease Rating Scale-Activity of Daily Living (UPDRS-ADL) and UPDRS-motor scores, and safety outcomes including adverse events (AE) and patient withdrawals, to determine indirect treatment comparison mean differences (MD) or hazard ratios (HR) with 95% confidence intervals (CI).
The indirect efficacy comparison resulted in a statistically nonsignificant off-time reduction difference (hours) of ropinirole-sustained release (SR) versus pramipexole-immediate release (MD − 0.25; 95% CI − 0.71, 0.21) and ropinirole-SR versus pramipexole-extended release (ER) (MD 0.18; 95% CI − 0.40, 0.76). Ropinirole-SR adjunctive treatment showed a tendency towards more improvement in UPDRS-ADL score (MD 1.24; 95% CI 0.23, 2.24) than adjunctive treatment of pramipexole-ER. Pramipexole-ER may be less likely to induce somnolence as an AE compared with ropinirole-SR (HR 0.46; 95% CI 0.23, 0.89). However, there were no statistically significant differences in UPDRS-motor score reduction, incidence of dyskinesia, hallucination, hypotension, insomnia and nausea, or withdrawals due to AE, for any reason.
Adjunctive therapy with ropinirole-SR or pramipexole appears to offer similar efficacy and tolerability in patients with advanced PD on the basis of this indirect comparison.
KeywordsIndirect treatment comparison Network meta-analysis Parkinson’s disease Pramipexole Ropinirole
Funding for this study (internal study number 206707/HO-16-17237) and the journal’s article processing charges was provided by GSK.
Medical Writing and/or Editorial Assistance
Editorial support in the form of formatting text, tables and figures and grammatical editing was provided by Jennie McLean, PhD, Fishawack Indicia Ltd, UK, and funded by GSK.
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
James Cooper is an employee of, and holds stocks/shares in GSK. Daniel Parks is an employee of, and holds stocks/shares in GSK. Rodrigo Refoios Camejo is an employee of, and holds stocks/shares in GSK. Hongxin Zhao was an employee of GSK at the time of the study and is now employed by Synyi AI, Shanghai, China. Yi Ning was an employee of GSK at the time of the study and is now employed by Meinian Institute of Health, Beijing, China and Peking University School of Public Health, Beijing, China. Xiajun Ni was an employee of GSK at the time of the study and is now employed by Eisai China Inc. Jiangsu Province, China. Bingming Yi was an employee of GSK at the time of the study and is now employed by Vertex Pharmaceuticals, Boston MA, USA
Compliance with Ethics Guidelines
This article does not contain any studies with human participants or animals performed by any of the authors.
Anonymised individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.
- 1.Poewe W. Parkinson disease. Nature Reviews Disease Primers. 2017;3:Article number: 17013Google Scholar
- 3.Stowe R, Ives N, Clarke CE, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev. 2010(7):CD007166.Google Scholar
- 6.Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry. 1999;66(4):436–41.CrossRefGoogle Scholar
- 7.Dias S, Welton NJ, Sutton AJ, Ades AE. A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London: NICE Decision Support Unit Technical Support Documents; 2014.Google Scholar
- 9.Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Inconsistency in networks of evidence based on randomised controlled trials. London: NICE Decision Support Unit Technical Support Documents; 2014.Google Scholar
- 19.Korczyn. Anti-Parkinson efficacy (L-dopa sparing effect) of ropinirole versus placebo as adjunct therapy in parkinsonian patients not optimally controlled on L-dopa. Confidential Report. 1990.Google Scholar
- 22.Hattori N, Nishioka H, Hasegawa K. Comparison of ropinirole controlled- and immediate-release in Japanese patients with advanced Parkinson's disease. Neurol Clin Neurosci. 2015;3(1):18–24. https://doi.org/10.1111/ncn3.128.
- 27.Zhang Z, Wang J, Zhang X, et al. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study. Parkinsonism Relat Disord. 2013;19(11):1022–6.CrossRefGoogle Scholar